论文标题
使用联合潜在类模型来描述复杂的疾病进展,用于多元纵向标记和临床终点
Describing complex disease progression using joint latent class models for multivariate longitudinal markers and clinical endpoints
论文作者
论文摘要
神经退行性疾病的特征是许多进展和临床终点标记。例如,多种系统萎缩(MSA)是一种罕见的神经退行性突触性疾病,其特征是进行性自主性失败和运动功能障碍的各种组合以及预后非常差。描述这种复杂和多维疾病的进展特别困难。随着时间的流逝,必须同时考虑对多变量标记的评估,临床终点的发生以及患者之间高度可疑的异质性。然而,这种描述对于理解疾病的自然病史,分期诊断患有疾病的患者,揭开亚表现型和预测预后至关重要。通过MSA进展的示例,我们展示了如何建模多个重复标记和临床终点的潜在类方法可以帮助描述复杂的疾病进展并确定用于探索新病理假设的亚表现型。提出的联合潜在类模型包括特定类的多元混合模型,以处理可能汇总到潜在维度和类别原因的比例比例危害模型以处理时间到事实数据的多元重复生物标志物。通过模拟验证的最大似然估计过程在LCMM R软件包中可用。在法国MSA队列中,包括598名患者的数据,最多13年,MSA的五种亚表征被鉴定出与生物标志物降解的序列和形状差异以及相关死亡风险的不同。在后验分析中,使用五个亚表格型来探索临床进展与外部成像和流体生物标志物之间的关联,同时适当地考虑了亚表型成员的不确定性。
Neurodegenerative diseases are characterized by numerous markers of progression and clinical endpoints. For instance, Multiple System Atrophy (MSA), a rare neurodegenerative synucleinopathy, is characterized by various combinations of progressive autonomic failure and motor dysfunction, and a very poor prognosis. Describing the progression of such complex and multi-dimensional diseases is particularly difficult. One has to simultaneously account for the assessment of multivariate markers over time, the occurrence of clinical endpoints, and a highly suspected heterogeneity between patients. Yet, such description is crucial for understanding the natural history of the disease, staging patients diagnosed with the disease, unravelling subphenotypes, and predicting the prognosis. Through the example of MSA progression, we show how a latent class approach modeling multiple repeated markers and clinical endpoints can help describe complex disease progression and identify subphenotypes for exploring new pathological hypotheses. The proposed joint latent class model includes class-specific multivariate mixed models to handle multivariate repeated biomarkers possibly summarized into latent dimensions and class-and-cause-specific proportional hazard models to handle time-to-event data. Maximum likelihood estimation procedure, validated through simulations is available in the lcmm R package. In the French MSA cohort comprising data of 598 patients during up to 13 years, five subphenotypes of MSA were identified that differ by the sequence and shape of biomarkers degradation, and the associated risk of death. In posterior analyses, the five subphenotypes were used to explore the association between clinical progression and external imaging and fluid biomarkers, while properly accounting for the uncertainty in the subphenotypes membership.